Key Highlights

  • ACCO Brands (NYSE:ACCO) trades at USD 5.46, USD 0.38 under its 52-week high of USD 5.84, with Tariff refunds lifting adjusted EPS.
  • Amneal Pharmaceuticals (NASDAQ:AMRX) dropped 4.97% to USD 20.44 after touching a 52-week high of USD 21.68, despite raising its 2026 guidance.
  • Alerus Financial (NASDAQ:ALRS) is at USD 34.63, up 4.40%, on 177,090 shares (relative Volume 1.46), with a USD 863.24 million market cap, a 52-week high of USD 34.72, a P/E of 29.32 and a 2.59% Dividend Yield on the 52-week high screen, captured November 4, 2026.
  • Arthur J. Gallagher (NYSE:AJG) is at USD 278.89, up 1.02%, on 2.80 million shares (relative volume 1.47), with a USD 71.48 billion market cap, a 52-week high of USD 281.53, a P/E of 42.60 and a 1.00% dividend yield on the 52-week high screen, captured November 4, 2026.

1. ACCO Brands (NYSE:ACCO)

On the 52-week high screen, ACCO Brands (NYSE:ACCO) is at USD 5.46, down 0.73%, on 3.87 million shares (relative volume 3.15), with a USD 504.00 million market cap, a 52-week high of USD 5.84, a P/E of 7.83 and a 5.45% dividend yield, captured November 4, 2026. A peak signals where the price stands, not whether it is cheap, so the results and valuation behind ACCO should be checked. Full-year adjusted EPS guidance sits at USD 0.98 to USD 1.02, including USD 0.12 of refunds. Published market data showed USD 4.68 on October 22, 2026, so the screen quote is about 16.7% higher by simple math, and the 52-week low back then was USD 2.811. The screen's valuation reads 7.83 on P/E with a 5.45% yield. The concern is that sales are declining, comparable sales fell 6.2%, and refunds lifting adjusted EPS will not recur.

2. Amneal Pharmaceuticals (NASDAQ:AMRX)

On the 52-week high screen, Amneal Pharmaceuticals (NASDAQ:AMRX) is at USD 20.44, down 4.97%, on 5.02 million shares (relative volume 1.17), with a USD 7.12 billion market cap, a 52-week high of USD 21.68, a P/E of 42.65 and EPS growth of 7,387.50%, captured November 4, 2026. Shares at peaks meet no resistance from earlier buyers, yet they have less room for error if results slow, which applies to AMRX. The company lifted 2026 net Revenue guidance to USD 3.15 billion to USD 3.25 billion and adjusted EPS guidance to USD 1.04 to USD 1.08. It trimmed Operating Cash Flow guidance to USD 325 million to USD 375 million from USD 350 million to USD 400 million. The cause of the 4.97% decline was not found; the GAAP loss and cash flow cut are features of the report, not confirmed reasons. The worry is a GAAP loss and lower cash flow outlook arriving with higher revenue guidance.

3. Alerus Financial (NASDAQ:ALRS)

Alerus Financial (NASDAQ:ALRS) rose 4.40% to USD 34.63, USD 0.09 under its 52-week high of USD 34.72. Peaks show where a price sits, not whether it is inexpensive, so the report and valuation behind ALRS Warrant attention. Third quarter 2026 Net Income was USD 19.2 million, per the company release headline, and second quarter net income was USD 20.9 million, or USD 0.81 per diluted share, in line with consensus. Piper Sandler lifted the stock to Overweight with a USD 38 target in early October 2026, and the board approved a buyback of up to 1.25 million shares on August 27, 2026. Third quarter EPS remains unverified, and the cause of the 4.40% jump was not found. The concern is unverified third quarter EPS, an unknown trigger for the jump, and a price reference older than the screen. Readers should weigh the release figures against the screen before drawing conclusions.

4. Addus HomeCare (NASDAQ:ADUS)

Addus HomeCare (NASDAQ:ADUS) trades at USD 125.75, USD 1.31 under its 52-week high of USD 127.06, following a USD 275.0 million agreement. Shares at highs have no overhead Supply from earlier holders, but they offer less cushion if results weaken, which applies to ADUS. Adjusted EPS was USD 1.83, up 17.3% from USD 1.56, and adjusted EBITDA reached USD 51.2 million, up 13.5%. No updated guidance came with the release. The concern is that AccentCare still needs regulatory approval, guidance was absent, and an analyst downgrade came ahead of the report.

5. Arthur J. Gallagher (NYSE:AJG)

Arthur J. Gallagher (NYSE:AJG) is at USD 278.89, USD 2.64 under its 52-week high of USD 281.53, with revenue up 18%. AJG qualifies for the list because it sits at or near its record price or its one year peak, a momentum signal. The company acquired The Mund Group on October 21, 2026 and a Melbourne firm on October 19, 2026, while Pen Underwriting bought Ornella Underwriting of Ireland on October 7, 2026; terms were not disclosed. The screen displays a P/E of 42.60 and EPS of USD 6.55. The worry is a P/E of 42.60 after a 46% climb from the low, undisclosed deal terms, and growth figures from one source.

Where Things Stand

The material reviewed does not establish why. AMRX dropped 4.97% after touching a 52-week high of USD 21.68 despite higher guidance, ALRS rose 4.40%, ADUS and AJG edged up, and ACCO eased 0.73%, so moves near a high can point either way on the same day. Record and 52-week high screens pick stocks at or near the top of their history or their one year range. They are momentum lists: a peak indicates the price level, not cheapness, and the report, valuation and one-time items behind each name decide whether the move is supported. Readers comparing these names should keep the screen date and the filing date apart, since the two can fall on different days.